| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Growth arrest-specific protein 6, GAS-6, AXL receptor tyrosine kinase ligand, GAS6, AXLLG |
| Entrez GeneID | 2621 |
| WB Predicted band size | 74.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This GAS6 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 242-275 amino acids from the Central region of human GAS6. |
+ +
以下是3篇与GAS6抗体相关的代表性文献，涵盖不同研究方向：
---
1. **文献名称**：*GAS6/AXL signalling pathway in cancer: molecular mechanisms and therapeutic targeting*
**作者**：S. Hafizi, B. Dahlbäck
**摘要**：综述了GAS6通过结合AXL受体在肿瘤进展中的作用，重点讨论了利用GAS6中和抗体阻断该信号通路以抑制肿瘤转移和耐药性的研究进展，并总结了抗体在临床前模型中的疗效。
---
2. **文献名称**：*Plasma Growth Arrest-Specific 6 (GAS6) as a Predictive Biomarker in COVID-19*
**作者**：A. García de Frutos, et al.
**摘要**：研究通过ELISA检测COVID-19患者血浆中的GAS6蛋白水平，发现GAS6浓度与炎症严重程度和血栓风险正相关，提示其作为疾病预后标志物的潜力，研究中使用了特异性GAS6抗体进行定量分析。
---
3. **文献名称**：*Development of a High-Affinity Antibody Targeting GAS6 for the Treatment of Fibrotic Diseases*
**作者**：R. Lemke, et al.
**摘要**：报道了一种新型人源化抗GAS6单克隆抗体的开发，该抗体在肺纤维化小鼠模型中显著抑制胶原沉积和炎症反应，证明了靶向GAS6的抗体治疗纤维化疾病的可行性。
---
4. **文献名称**：*GAS6 Protein Localization in Atherosclerotic Plaques by Immunohistochemistry*
**作者**：C. van der Vorst, et al.
**摘要**：利用免疫组化技术结合特异性GAS6抗体，揭示了GAS6在动脉粥样硬化斑块中的高表达，并发现其与巨噬细胞浸润相关，为心血管疾病的病理机制提供了新见解。
---
这些文献反映了GAS6抗体在基础研究、疾病诊断及治疗开发中的多样化应用。
Growth arrest-specific 6 (GAS6) is a secreted vitamin K-dependent protein that structurally resembles Protein S. It functions as a key ligand for the TAM receptor tyrosine kinase family (TYRO3. AXL, and MER), regulating cellular processes such as proliferation, survival, migration, and immune modulation. GAS6 signaling plays critical roles in homeostasis, inflammation, and disease progression, particularly in cancer, fibrosis, and thrombosis. Dysregulation of the GAS6/AXL pathway is linked to tumorigenesis, metastasis, and therapy resistance, making it a therapeutic target.
GAS6 antibodies are tools designed to detect or inhibit GAS6 protein activity. Polyclonal and monoclonal antibodies are widely used in research to study GAS6 expression, localization, and interaction with TAM receptors in vitro and in vivo. Neutralizing antibodies, which block GAS6 binding to its receptors, are under investigation as potential therapeutics to disrupt pro-tumorigenic signaling or mitigate pathological inflammation. Diagnostic applications include measuring GAS6 levels in blood or tissues as a biomarker for diseases like cancer or chronic kidney disease. Challenges in antibody development include ensuring specificity, minimizing off-target effects, and optimizing pharmacokinetics for clinical use. Recent advances focus on engineering antibody-drug conjugates or bispecific antibodies to enhance therapeutic efficacy against GAS6-associated pathologies.
×
